Jean M. Franchi - 17 Feb 2026 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Role
Chief Financial Officer
Signature
By: /s/ Rahul Khara, as Attorney-in-Fact
Issuer symbol
IRON
Transactions as of
17 Feb 2026
Net transactions value
-$719,727
Form type
4
Filing time
19 Feb 2026, 17:42:56 UTC
Previous filing
11 Feb 2026
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Franchi Jean M. Chief Financial Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN By: /s/ Rahul Khara, as Attorney-in-Fact 19 Feb 2026 0001653053

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRON Common Stock Sale $256,154 -4,075 -4.9% $62.86 78,424 17 Feb 2026 Direct F1
transaction IRON Common Stock Sale $220,838 -3,397 -4.3% $65.01 75,027 18 Feb 2026 Direct F2, F3
transaction IRON Common Stock Sale $242,735 -3,684 -4.9% $65.89 71,343 18 Feb 2026 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.47 to $65.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.51 to $66.38, inclusive.